← All companies
ARTV
Artiva Biotherapeutics, Inc.
$10.76
+0.33 +3.16%
Key statistics
from XBRL data in SEC filingsMarket cap
$266M
Revenue (TTM)
$0.00
Net income (TTM)
-$87.1M
EPS (TTM)
$-3.55
P/E ratio
—
Dividend yield
—
Free cash flow
-$79.3M
Cash
$21.0M
Total assets
$106M
Gross margin
—
52-week range
$2.22 – $14.53
Recent SEC filings
40 most recentAnnual, quarterly & current reports
8-K
Other events
Jul 22, 2026
8-K
Director or officer change
May 19, 2026
8-K
Other events
May 8, 2026
10-Q
Quarter ended 2026-03-31
May 8, 2026
8-K
Results of operations (earnings release); Regulation FD disclosure; Other events
May 8, 2026
10-K/A
Fiscal year ended 2025-12-31
Apr 30, 2026
10-K
Fiscal year ended 2025-12-31
Mar 10, 2026
8-K
Results of operations (earnings release)
Mar 10, 2026
8-K
Director or officer change
Feb 24, 2026
8-K
Director or officer change
Feb 19, 2026
8-K
Director or officer change
Dec 12, 2025
8-K
Regulation FD disclosure; Other events
Nov 12, 2025
10-Q
Quarter ended 2025-09-30
Nov 12, 2025
8-K
Results of operations (earnings release)
Nov 12, 2025
10-Q
Quarter ended 2025-06-30
Aug 6, 2025
8-K
Results of operations (earnings release)
Aug 6, 2025
8-K
Director or officer change; Shareholder vote results
Jun 25, 2025
10-Q
Quarter ended 2025-03-31
May 8, 2025
8-K
Results of operations (earnings release)
May 8, 2025
10-K
Fiscal year ended 2024-12-31
Mar 24, 2025
8-K
Results of operations (earnings release)
Mar 24, 2025
8-K
Director or officer change
Jan 29, 2025
10-Q
Quarter ended 2024-09-30
Nov 12, 2024
8-K
Results of operations (earnings release)
Nov 12, 2024
8-K
Director or officer change
Oct 22, 2024
10-Q
Quarter ended 2024-06-30
Aug 29, 2024
8-K
Results of operations (earnings release)
Aug 29, 2024
8-K
Amended charter or bylaws
Jul 22, 2024
Other filings
ARS
Aug 3, 2026
DEF 14A
Aug 3, 2026
4
Jul 31, 2026
4
Jul 28, 2026
SCHEDULE 13D/A
Jul 23, 2026
4
Jul 23, 2026
4/A
Jul 23, 2026
4
Jul 20, 2026
4
Jul 14, 2026
4
Jun 29, 2026
4
Jun 16, 2026
SCHEDULE 13D/A
Jun 15, 2026